NCT06530524View on ClinicalTrials.gov

Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

December 1, 2027

Conditions
Head Neck CancerXerostomia Following Radiotherapy
Interventions
DRUG

OnabotulinumtoxinA

Injection of onabotulinumtoxinA into the at-risk major salivary glands

DRUG

Placebo

Injection of normal saline into the at-risk major salivary glands

Trial Locations (1)

Unknown

McGill University, Montreal

All Listed Sponsors
collaborator

Lady Davis Institute

OTHER

collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

lead

Sir Mortimer B. Davis - Jewish General Hospital

OTHER

NCT06530524 - Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery | Biotech Hunter | Biotech Hunter